Search

Your search keyword '"Pong RC"' showing total 44 results

Search Constraints

Start Over You searched for: Author "Pong RC" Remove constraint Author: "Pong RC"
44 results on '"Pong RC"'

Search Results

1. IFNgamma-Induced IFIT5 Promotes Epithelial-to-Mesenchymal Transition in Prostate Cancer via miRNA Processing

2. SPHK1 promotes bladder cancer metastasis via PD-L2/c-Src/FAK signaling cascade.

3. Therapeutic targeting of histone lysine demethylase KDM4B blocks the growth of castration-resistant prostate cancer.

4. The central role of Sphingosine kinase 1 in the development of neuroendocrine prostate cancer (NEPC): A new targeted therapy of NEPC.

5. Histone lysine demethylase KDM4B regulates the alternative splicing of the androgen receptor in response to androgen deprivation.

6. Activation of sphingosine kinase by lipopolysaccharide promotes prostate cancer cell invasion and metastasis via SphK1/S1PR4/matriptase.

7. The roles and mechanism of IFIT5 in bladder cancer epithelial-mesenchymal transition and progression.

8. Developing new targeting strategy for androgen receptor variants in castration resistant prostate cancer.

9. Targeting 3-phosphoinositide-dependent protein kinase 1 associated with drug-resistant renal cell carcinoma using new oridonin analogs.

10. Nanoparticle Targeting CD44-Positive Cancer Cells for Site-Specific Drug Delivery in Prostate Cancer Therapy.

11. Loss of DAB2IP in RCC cells enhances their growth and resistance to mTOR-targeted therapies.

12. DAB2IP loss confers the resistance of prostate cancer to androgen deprivation therapy through activating STAT3 and inhibiting apoptosis.

13. Sensitization of radio-resistant prostate cancer cells with a unique cytolethal distending toxin.

14. The mechanism of DAB2IP in chemoresistance of prostate cancer cells.

15. Slug, a unique androgen-regulated transcription factor, coordinates androgen receptor to facilitate castration resistance in prostate cancer.

16. Analysis of oligo-arginine cell-permeable peptides uptake by prostate cells.

17. Upregulation of TRAG3 gene in urothelial carcinoma of the bladder.

18. Evidence of epithelial to mesenchymal transition associated with increased tumorigenic potential in an immortalized normal prostate epithelial cell line.

19. Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis.

20. DAB2IP coordinates both PI3K-Akt and ASK1 pathways for cell survival and apoptosis.

21. Efficient solid-phase synthesis of FK228 analogues as potent antitumoral agents.

22. Decreased DOC-2/DAB2 expression in urothelial carcinoma of the bladder.

23. A histone deacetylase inhibitor enhances adenoviral infection of renal cancer cells.

24. Mechanism of increased coxsackie and adenovirus receptor gene expression and adenovirus uptake by phytoestrogen and histone deacetylase inhibitor in human bladder cancer cells and the potential clinical application.

25. Enhanced transgene expression in urothelial cancer gene therapy with histone deacetylase inhibitor.

26. The role of cell adhesion molecule in cancer progression and its application in cancer therapy.

27. Epigenetic regulation of coxsackie and adenovirus receptor (CAR) gene promoter in urogenital cancer cells.

28. Surrogate marker for predicting the virus binding of urogenital cancer cells during adenovirus-based gene therapy.

29. The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2.

30. Cell adhesion proteins as tumor suppressors.

31. Differential regulation of the human gene DAB2IP in normal and malignant prostatic epithelia: cloning and characterization.

32. The mechanism of the growth-inhibitory effect of coxsackie and adenovirus receptor (CAR) on human bladder cancer: a functional analysis of car protein structure.

33. The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy.

34. The growth inhibitory effect of p21 adenovirus on human bladder cancer cells.

35. The role of DOC-2/DAB2 protein phosphorylation in the inhibition of AP-1 activity. An underlying mechanism of its tumor-suppressive function in prostate cancer.

36. Structural analysis of the C-CAM1 molecule for its tumor suppression function in human prostate cancer.

37. Adenovirus-mediated p21((WAF1/SDII/CIP1)) gene transfer induces apoptosis of human cervical cancer cell lines.

38. Induction of apoptosis and G2/M cell cycle arrest by DCC.

39. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy.

40. Attenuation of WAF1/Cip1 expression by an antisense adenovirus expression vector sensitizes glioblastoma cells to apoptosis induced by chemotherapeutic agents 1,3-bis(2-chloroethyl)-1-nitrosourea and cisplatin.

41. Regulation of rat DOC-2 gene during castration-induced rat ventral prostate degeneration and its growth inhibitory function in human prostatic carcinoma cells.

42. Adenovirus-mediated expression of PML suppresses growth and tumorigenicity of prostate cancer cells.

43. Involvement of protein kinase C activation in ornithine decarboxylase gene expression in primary culture of newborn mouse epidermal cells and in skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate.

44. Mechanisms involved in ornithine decarboxylase induction by 12-O-tetradecanoylphorbol-13-acetate, a potent mouse skin tumor promoter and an activator of protein kinase C.

Catalog

Books, media, physical & digital resources